In patients with CSCC that had spread or could not be cured by surgery or radiation LIBTAYO helped tumors shrink or completely disappear in almost half of clinical trial patients

LIBTAYO was studied in clinical trials

LIBTAYO has been studied in 108 patients in 2 ongoing clinical trials of patients with CSCC that had spread or could not be cured by surgery or radiation.

LIBTAYO helped tumors shrink or completely disappear in almost half of patients with advanced CSCC that had spread or could not be cured by surgery or radiation

47.2% of patients
(51 of 108) saw an improvement in their condition with LIBTAYO (objective response rate)

Complete response3.7% of patients (4 of 108)
saw tumors disappear completely
Partial response43.5% of patients (47 of 108)
saw tumors shrink meaningfully

In 80% (41 of 51) of patients who saw an improvement with LIBTAYO, the effect was still ongoing at the time of last follow-up.

Responses lasted 6 months or longer in 61% (31 of 51) of patients who responded to LIBTAYO.

Responses lasted between 1 month and 15.2+ months (still ongoing at time of last follow-up).

Patient examples